NovaBridge Biosciences
Qualité des données : 83%
NBP
NASDAQ
Manufacturing
Chemicals
2,36 €
0,00 €
(0,00%)
Cap. Boursière: 277,85 M
Prix
2,41 €
Cap. Boursière
277,85 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue declined -53,75% annually over 5 years
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 53,75%
Capital efficient — spends only 1,11% of revenue on capex
Croissance
Revenue Growth (5Y)
-53,75%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-20,31%
Au-dessus de la moyenne du secteur (-54,01%)
ROIC-32,33%
Net Margin-7321,04%
Op. Margin-14915,98%
Sécurité
Debt / Equity
N/A
Current Ratio14,47
Interest CoverageN/A
Valorisation
PE (TTM|NTM)
-6,01 | -2,23
En dessous de la moyenne du secteur (-1,49)
P/B Ratio1,07
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -6,0 | -1,5 |
| P/B | 1,1 | 1,6 |
| ROE % | -20,3 | -54,0 |
| Net Margin % | -7321,0 | -41,5 |
| Rev Growth 5Y % | -53,8 | 1,8 |
| D/E | — | 0,3 |
Objectif de Cours des Analystes
4 analystes
Buy
Actuel
2,36 €
Objectif
8,25 €
7,00 €
8,50 €
9,00 €
Prévisions
P/E Prévisionnel
-2,23
BPA Prévisionnel
-1,06 €
CA Est.
0,0
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-1,06 €
-1,06 € – -1,06 €
|
0,0 | 1 |
| FY2026 |
-0,94 €
-0,94 € – -0,94 €
|
0,0 | 1 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,24 €
-0,24 € – -0,24 €
|
0,0 | 1 |
| 2026 Q1 |
-0,23 €
-0,23 € – -0,23 €
|
0,0 | 1 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,08 € | -0,31 € | -287,5% |
| Q32025 | -0,05 € | -0,06 € | -20,0% |
| Q22025 | -0,12 € | -0,07 € | +41,7% |
| Q12025 | -0,07 € | -0,04 € | +42,9% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,00% | Revenue Growth (3Y) | -59,71% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -53,75% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 632 000,0 | Net Income (TTM) | -46,27 M |
| ROE | -20,31% | ROA | -19,11% |
| Gross Margin | N/A | Operating Margin | -14915,98% |
| Net Margin | -7321,04% | Free Cash Flow (TTM) | N/A |
| ROIC | -32,33% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 14,47 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 216,68 M | Tangible Book Value | 258,92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6,01 | Forward P/E | -2,23 |
| P/B Ratio | 1,07 | P/S Ratio | 439,64 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | N/A | ||
| Market Cap | 277,85 M | Enterprise Value | 49,79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,21 | Revenue / Share | 0,01 |
| FCF / Share | N/A | OCF / Share | N/A |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1,11% | FCF Conversion | N/A |
| SBC-Adj. FCF | N/A | Growth Momentum | 53,75 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 632 000,0 | 632 000,0 | 3,89 M | -32,12 M | 13,81 M |
| Net Income | -46,27 M | -22,23 M | -206,44 M | -363,53 M | -365,87 M |
| EPS (Diluted) | -0,21 | -0,12 | -1,08 | -1,92 | -2,09 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -94,27 M | -51,43 M | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 62,91 M | 21,77 M | 114,18 M | 131,20 M | 190,34 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | 300 000,0 | 3,40 M | 3,70 M | — |
| Interest Expense | — | — | 102 000,0 | 1 000,0 | 0,0 |
| Income Tax | 0,0 | 0,0 | — | 101 000,0 | -495 000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 260,52 M | 212,68 M | 368,03 M | 590,63 M | 878,95 M |
| Total Liabilities | 29,58 M | 11,52 M | 126,03 M | 168,73 M | 163,45 M |
| Shareholders' Equity | 230,94 M | 201,16 M | 242,00 M | 421,90 M | 715,50 M |
| Total Debt | — | — | 4,22 M | 2,75 M | — |
| Cash & Equivalents | 210,63 M | 68,26 M | 301,62 M | 465,99 M | 552,94 M |
| Current Assets | 217,52 M | 176,69 M | 329,11 M | 525,79 M | 750,36 M |
| Current Liabilities | 26,89 M | 8,45 M | 58,00 M | 109,92 M | 97,92 M |
{"event":"ticker_viewed","properties":{"ticker":"NBP","listing_kind":"stock","pathname":"/stocks/nbp","exchange":"NASDAQ","country":"US"}}